AIM · Aim Immunotech Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.0K | - | $26.0K | $25.0K | $16.0K | - | $35.0K | $50.0K | $40.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $482.0K | - | $607.0K | $1.17M | $1.08M | - | $1.44M | $1.15M | $1.95M | - |
| SG&A | $1.76M | - | $1.80M | $1.49M | $2.54M | - | $3.08M | $2.59M | $3.81M | - |
| Total Operating Expenses | $2.25M | - | $2.47M | $2.67M | $3.63M | - | $4.52M | $3.74M | $5.77M | - |
| D&A | $9.0K | - | - | - | $10.0K | - | - | - | $9.0K | - |
| Operating Income | ($2.23M) | - | ($2.45M) | ($2.65M) | ($3.62M) | - | ($4.49M) | ($3.69M) | ($5.73M) | - |
| Interest Expense | $304.0K | - | $148.0K | $149.0K | $124.0K | - | $202.0K | $179.0K | $72.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($3.02M) | - | ($3.28M) | ($2.79M) | ($3.71M) | - | ($3.70M) | ($1.84M) | ($5.82M) | - |
| EPS - Basic | ($0.69) | - | $1.52 | ($3.57) | ($4.85) | - | ($5.82) | ($2.91) | ($11.64) | - |
| EPS - Diluted | ($0.69) | - | $1.52 | ($3.57) | ($4.85) | - | ($5.82) | ($2.91) | ($11.64) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.82M | $2.98M | $2.35M | $476.0K | $898.0K | $1.70M | $915.0K | $3.55M | $3.29M | $5.44M |
| Accounts Receivable | - | $7.0K | - | - | - | - | - | - | - | $1.18M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.22M | $1.63M | $1.25M | $7.30M | $6.94M | $6.38M | $6.26M | $5.46M | $6.57M | $6.44M |
| Current Assets | $6.21M | $3.29M | $2.58M | $1.02M | $2.58M | $4.18M | $7.57M | $10.36M | $11.31M | $14.56M |
| Total Assets | $8.59M | $5.78M | $5.49M | $4.13M | $6.25M | $8.61M | $13.59M | $15.71M | $16.19M | $19.38M |
| Current Liabilities | $6.14M | $6.22M | $4.04M | $10.39M | $9.77M | $9.54M | $10.10M | $8.84M | $9.88M | $8.65M |
| Long-term Debt | $210.0K | $927.0K | - | $2.72M | $2.39M | $2.81M | $139.0K | $283.0K | $950.0K | - |
| Total Liabilities | $6.46M | $15.56M | $11.57M | $10.68M | $10.11M | $9.93M | $10.68M | $9.61M | $11.36M | $9.15M |
| Stockholders' Equity | $2.13M | ($9.78M) | ($6.08M) | ($6.55M) | $6.00M | ($1.32M) | $2.91M | $6.10M | $4.83M | $10.23M |
| Retained Earnings | ($443.81M) | ($440.79M) | ($436.61M) | ($433.33M) | ($430.53M) | ($426.83M) | ($420.86M) | ($417.16M) | ($415.32M) | ($409.51M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.72M) | - | - | - | ($2.36M) | - | - | - | ($4.82M) | - |
| Investing Cash Flow | ($37.0K) | - | - | - | $898.0K | - | - | - | ($158.0K) | - |
| Financing Cash Flow | $5.59M | - | - | - | $660.0K | - | - | - | $2.83M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -10118.2% | - | -9411.5% | -10584.0% | -22618.8% | - | -12825.7% | -7388.0% | -14335.0% | - |
| EBITDA margin | -10077.3% | - | - | - | -22556.3% | - | - | - | -14312.5% | - |
| Net margin | -13740.9% | - | -12630.8% | -11176.0% | -23156.3% | - | -10571.4% | -3672.0% | -14542.5% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 2190.9% | - | 2334.6% | 4696.0% | 6750.0% | - | 4105.7% | 2290.0% | 4877.5% | - |
| SG&A / Revenue | 8009.1% | - | 6915.4% | 5948.0% | 15906.3% | - | 8797.1% | 5182.0% | 9537.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -35.2% | - | -59.8% | -67.7% | -59.3% | - | -27.2% | -11.7% | -35.9% | - |
| Return on equity | -142.3% | - | 54.0% | 42.7% | -61.8% | - | -127.1% | -30.1% | -120.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.01 | 0.53 | 0.64 | 0.10 | 0.26 | 0.44 | 0.75 | 1.17 | 1.14 | 1.68 |
| Quick ratio | 1.01 | 0.53 | 0.64 | 0.10 | 0.26 | 0.44 | 0.75 | 1.17 | 1.14 | 1.68 |
| Cash ratio | 0.95 | 0.48 | 0.58 | 0.05 | 0.09 | 0.18 | 0.09 | 0.40 | 0.33 | 0.63 |
| Leverage | ||||||||||
| Debt / Equity | 0.10 | -0.09 | - | -0.42 | 0.40 | -2.12 | 0.05 | 0.05 | 0.20 | - |
| Debt / Assets | 0.02 | 0.16 | - | 0.66 | 0.38 | 0.33 | 0.01 | 0.02 | 0.06 | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -7.3x | - | -16.5x | -17.8x | -29.2x | - | -22.2x | -20.6x | -79.6x | - |
| Equity multiplier | 4.04 | -0.59 | -0.90 | -0.63 | 1.04 | -6.51 | 4.67 | 2.58 | 3.35 | 1.89 |
| Liabilities / Assets | 0.75 | 2.69 | 2.11 | 2.59 | 1.62 | 1.15 | 0.79 | 0.61 | 0.70 | 0.47 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.01 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | 1.7x | - | - | - | - | - | - | - |
| P / B | 1.2x | - | - | - | 136.4x | - | 518.7x | 310.8x | 467.2x | - |
| P / S | 116.7x | - | 214.0x | 254.8x | 51161.4x | - | 43155.9x | 37924.1x | 56365.8x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 37.5% | - | -25.7% | -50.0% | -60.0% | - | -23.9% | 19.0% | -18.4% | - |
| Revenue CAGR (3y) | -23.4% | - | 7.4% | -5.9% | -21.4% | - | 2.0% | 29.5% | 12.6% | - |
| Revenue CAGR (5y) | -4.7% | - | -6.3% | -9.0% | -18.7% | - | -1.6% | 11.5% | -6.5% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 38.5% | - | 45.5% | 28.4% | 36.9% | - | 45.0% | 32.4% | -33.5% | - |
| Net income growth (YoY) | 18.4% | - | 11.2% | -52.2% | 36.3% | - | 52.7% | 62.6% | -58.9% | - |
| EPS growth (YoY) | 85.8% | - | - | -22.7% | 58.3% | - | -4376.6% | -2809.8% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -64.6% | -640.0% | - | - | 24.3% | - | -87.1% | -79.8% | -86.2% | -73.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$135.0K totalClinical Treatment Programs US$135.0K · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing AIM ImmunoTech Inc. against the 5 most active filers in the same SIC group.